Discounted Cash Flow (DCF) Analysis Levered

Cognition Therapeutics, Inc. (CGTX)

$1.86

+0.09 (+5.08%)
All numbers are in Millions, Currency in USD

Free Cash Flow

Year
A/P
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue --------
Revenue (%)
Operating Cash Flow --------
Operating Cash Flow (%)
Capital Expenditure --------
Capital Expenditure (%)
Free Cash Flow --------

Weighted Average Cost Of Capital

Share price $ 1.86
Beta 0.000
Diluted Shares Outstanding 21.37
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 5.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 3.500
Total Debt -
Total Equity 39.75
Total Capital 39.75
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash Flow

Year
A/P
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue --------
Operating Cash Flow --------
Capital Expenditure --------
Free Cash Flow --------
WACC
PV LFCF --------
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 3.50
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -54.72
Equity Value -
Shares Outstanding 21.37
Equity Value Per Share -